loading page

The beneficial effects of RAS Blockades on insulin sensitivity, metabolic cytokines and glycemic control in non-diabetic patients: a meta-analysis
  • +1
  • Sai Tian,
  • Rong Huang,
  • Ke An,
  • Shaohua Wang
Sai Tian
Affiliated Zhongda Hospital of Southeast University
Author Profile
Rong Huang
Southeast University
Author Profile
Ke An
Southeast University
Author Profile
Shaohua Wang
ZhongDa Hospital of Southeast University
Author Profile


Background: To investigate the comparative effects of Renin-Angiotensin System (RAS) Blockades and other antihypertensive agents on insulin sensitivity, metabolic cytokines and glycemic control in non-diabetic patients. Methods: We searched for the relevant articles published on MEDLINE, EMBASE, Cochrane Library and Web of Science. 29 randomized control trials that investigated the use of Angiotensin-converting enzyme inhibitors (ACEI) or Angiotensin receptor blockers (ARB) versus active comparator or placebo to determine the effects on insulin sensitivity and glycemic index in non-diabetics were included. Subgroup and meta-regression analyses were performed to explore potential sources of heterogeneity. Results: RAS Blockades significantly decreased the homeostasis model assessment of insulin resistance and fasting plasma glucose (WMD −0.69, 95% CI −1.01 to −0.38, p < 0.001; WMD −0.09 mmol/L, 95% CI −0.15 to −0.03, p = 0.003, respectively), while increased the quantitative insulin sensitivity check index (WMD 0.02, 95% CI 0.01 to 0.03, p < 0.001) among non-diabetic patients. Besides, RAS Blockades significantly decreased hsCRP and TNF-α (WMD −0.41 mg/L, 95% CI −0.70 to −0.11, p = 0.007; WMD −0.21 ng/mL, 95% CI −0.30 to −0.13, p < 0.001, respectively), while increased adiponectin and potassium (WMD 0.46 μg/mL, 95% CI 0.14 to 0.78, p = 0.005; WMD 0.24 mmol/l, 95% CI 0.10 to 0.39, p = 0.001, respectively). Conclusions: RAS Blockades are superior to other antihypertensive agents in improving insulin sensitivity, glycemic control and some metabolic cytokines in non-diabetic patients, indicating a better antihypertensive choice, which probably delays the onsets of diabetes.